INTERVENTION 1:	Intervention	0
Xeloda (Capecitabine)	Intervention	1
capecitabine	CHEBI:31348	8-20
1000 mgrs/m2 twice a day, tablets, 8 cycles	Intervention	2
day	UO:0000033	21-24
Capecitabine	Intervention	3
capecitabine	CHEBI:31348	0-12
INTERVENTION 2:	Intervention	4
Observation	Intervention	5
Observation. No intervention.	Intervention	6
Inclusion Criteria:	Eligibility	0
Written informed consent.	Eligibility	1
Histological diagnoses of operable invasive adenocarcinoma of the breast (T1-T3). Tumours must be HER2 negative. Time window between end of adjuvant chemotherapy and study randomization must be less than 8 weeks. In patients receiving adjuvant radiotherapy, time window allowed between last session and randomisation is 4 weeks.	Eligibility	2
adenocarcinoma	DOID:299	44-58
breast	UBERON:0000310	66-72
time	PATO:0000165	113-117
time	PATO:0000165	258-262
adjuvant	CHEBI:60809	140-148
adjuvant	CHEBI:60809	235-243
radiotherapy	OAE:0000235	244-256
Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection. Margins free of disease and ductal carcinoma in-situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.	Eligibility	3
surgery	OAE:0000067	0-7
surgery	OAE:0000067	51-58
lymph	UBERON:0002391	73-78
disease	DOID:4,OGMS:0000031	112-119
carcinoma	HP:0030731,DOID:305	131-140
carcinoma	HP:0030731,DOID:305	178-187
Node negative patients with tumour size > 2 cm.	Eligibility	4
size	PATO:0000117	35-39
Positive axillary lymph nodes defined as at least 1 out of 6 nodes with presence of disease. If sentinel node technique is used, sentinel node can be the only node affected. Patients belonging to the following classifications are eligible: pN1a (Metastases in 1-3 axillary lymph nodes, at least one metastasis greater than 2.0 mm), pN2a (Metastases in 4-9 axillary lymph nodes (at least one tumor deposit greater than 2 mm)), pN3a (Metastases in 10 or more axillary lymph nodes [at least one tumor deposit greater than 2 mm]; or metastases to the infraclavicular [level III axillary lymph] nodes).	Eligibility	5
lymph	UBERON:0002391	18-23
lymph	UBERON:0002391	273-278
lymph	UBERON:0002391	365-370
lymph	UBERON:0002391	466-471
lymph	UBERON:0002391	583-588
disease	DOID:4,OGMS:0000031	84-91
affected	HP:0032320	164-172
Status of hormone receptors in primary tumour. Negative results must be available before the end of adjuvant chemotherapy.	Eligibility	6
hormone	CHEBI:24621	10-17
adjuvant	CHEBI:60809	100-108
Patients must not present evidence of metastatic disease.	Eligibility	7
present	PATO:0000467	18-25
disease	DOID:4,OGMS:0000031	49-56
Negative status of HER2 in primary tumour, known before randomization.	Eligibility	8
Adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines and/or taxanes.	Eligibility	9
adjuvant	CHEBI:60809	0-8
Age >= 18 and <= 70 years old.	Eligibility	10
age	PATO:0000011	0-3
Performance status (Karnofsky index) >= 80.	Eligibility	11
Laboratory results (within 14 days prior to randomization):	Eligibility	12
Hematology:	Eligibility	13
neutrophils >= 1.5 x 10e9/l;	Eligibility	14
x	LABO:0000148	19-20
platelets >= 100x 10e9/l;	Eligibility	15
hemoglobin >= 10 mg/dl	Eligibility	16
hemoglobin	CHEBI:35143	0-10
Hepatic function:	Eligibility	17
function	BAO:0003117,BFO:0000034	8-16
total bilirubin <= 1 upper normal limit (UNL);	Eligibility	18
Aspartate aminotransferase (AST or SGOT) and Alanine aminotransferase (ALT or SGPT) <= 2.5 UNL;	Eligibility	19
aspartate	CHEBI:29995	0-9
alanine	CHEBI:16449	45-52
alkaline phosphatase <= 2.5 UNL.	Eligibility	20
phosphatase	GO:0016791,BAO:0000295	9-20
If values of SGOT and SGPT > 1.5 UNL are associated to alkaline phosphatase > 2.5 UNL, patient is not eligible.	Eligibility	21
phosphatase	GO:0016791,BAO:0000295	64-75
patient	HADO:0000008,OAE:0001817	87-94
Renal Function:	Eligibility	22
function	BAO:0003117,BFO:0000034	6-14
creatinine <= 175 Âµmol/l (2 mg/dl).	Eligibility	23
creatinine	CHEBI:16737	0-10
creatinine clearance >= 60 ml/min.	Eligibility	24
creatinine clearance	CMO:0000765	0-20
Pharmacogenetics:	Eligibility	25
one blood sample is needed for single nucleotide polymorphism (SNP) assessment.	Eligibility	26
blood	UBERON:0000178	4-9
nucleotide	CHEBI:36976,BAO:0002010	38-48
Patients able to comply with treatment and study follow-up.	Eligibility	27
Negative pregnancy test done in the 14 previous days to randomization.	Eligibility	28
Exclusion Criteria:	Eligibility	29
Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any malignancy.	Eligibility	30
paclitaxel	CHEBI:45863	46-56
Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments. Negative pregnancy test in the 14 previous days to randomization.	Eligibility	31
hormone	CHEBI:24621	97-104
Bilateral invasive breast cancer.	Eligibility	32
bilateral	HP:0012832	0-9
breast cancer	DOID:1612	19-32
Any T4 or M1 tumour.	Eligibility	33
m1	CHEBI:34826	10-12
Axillary lymph nodes: patients belonging to the following classifications are excluded: pN1b (Metastases in internal mammary nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected), pN1c (Metastases in 1-3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected), pN2b (Metastases in clinically detected internal mammary lymph nodes in the absence of axillary lymph node metastases), pN3b (Metastases in clinically detected ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected), pN3c (Metastases in ipsilateral supraclavicular lymph nodes).	Eligibility	34
lymph	UBERON:0002391	9-14
lymph	UBERON:0002391	192-197
lymph	UBERON:0002391	273-278
lymph	UBERON:0002391	309-314
lymph	UBERON:0002391	382-387
lymph	UBERON:0002391	487-492
lymph	UBERON:0002391	526-531
lymph	UBERON:0002391	619-624
lymph	UBERON:0002391	680-685
lymph	UBERON:0002391	724-729
lymph	UBERON:0002391	760-765
lymph	UBERON:0002391	833-838
lymph	UBERON:0002391	929-934
excluded	HP:0040285	78-86
Any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year, uncontrolled hypertension or high risk arrhythmias.	Eligibility	35
congestive heart failure	HP:0001635,DOID:6000	45-69
history	BFO:0000182	88-95
myocardial infarction	HP:0001658,DOID:5844	99-120
year	UO:0000036	141-145
hypertension	HP:0000822,DOID:10763	160-172
History of neurological or psychiatric disorders, which could preclude the patients to free informed consent.	Eligibility	36
history	BFO:0000182	0-7
Active uncontrolled infection.	Eligibility	37
active	PATO:0002354	0-6
Active peptic ulcer, unstable diabetes mellitus.	Eligibility	38
active	PATO:0002354	0-6
peptic ulcer	HP:0004398	7-19
diabetes mellitus	HP:0000819,DOID:9351	30-47
Previous or current history of neoplasms different to breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.	Eligibility	39
history	BFO:0000182	20-27
breast cancer	DOID:1612	54-67
skin carcinoma	DOID:3451	80-94
in situ carcinoma	DOID:8719	105-122
in situ carcinoma	DOID:8719	215-232
in situ carcinoma	DOID:8719	261-278
breast	UBERON:0000310	54-60
breast	UBERON:0000310	245-251
History of hypersensitivity to capecitabine, fluorouracil.	Eligibility	40
history	BFO:0000182	0-7
hypersensitivity	GO:0002524,DOID:1205	11-27
capecitabine	CHEBI:31348	31-43
Patients lacking physical integrity of upper gastrointestinal tract or with history of bad absorption syndrome.	Eligibility	41
history	BFO:0000182	76-83
syndrome	DOID:225	102-110
History of dihydropyrimidine dehydrogenase (DPD) deficiency.	Eligibility	42
history	BFO:0000182	0-7
Anticoagulant treatment with coumadin anticoagulants.	Eligibility	43
anticoagulant	CHEBI:50249	0-13
anticoagulant	CHEBI:50249	38-51
Current treatment with sorivudine or its chemical family.	Eligibility	44
sorivudine	CHEBI:32152	23-33
Concomitant treatment with other investigational products. Participation in other clinical trials with a non-marketed drug in the 30 previous days before randomization.	Eligibility	45
drug	CHEBI:23888	118-122
Concomitant treatment with other therapy for cancer.	Eligibility	46
cancer	DOID:162	45-51
Males.	Eligibility	47
Outcome Measurement:	Results	0
Disease Free Survival (DFS) Events	Results	1
disease	DOID:4,OGMS:0000031	0-7
DFS was measured from the date of randomization assignment in the intent to treat (ITT) population to loco-regional or distant recurrence, second primary malignancy or death date, whichever occurred first.	Results	2
second	UO:0000010	139-145
death	OAE:0000632	168-173
Time frame: 5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Xeloda (Capecitabine)	Results	5
capecitabine	CHEBI:31348	25-37
Arm/Group Description: 1000 mgrs/m2 twice a day, tablets, 8 cycles	Results	6
day	UO:0000033	44-47
Capecitabine	Results	7
capecitabine	CHEBI:31348	0-12
Overall Number of Participants Analyzed: 448	Results	8
Measure Type: Count of Participants	Results	9
Unit of Measure: Participants  105  23.4%	Results	10
Results 2:	Results	11
Arm/Group Title: Observation	Results	12
Arm/Group Description: Observation. No intervention.	Results	13
Overall Number of Participants Analyzed: 428	Results	14
Measure Type: Count of Participants	Results	15
Unit of Measure: Participants  120  28.0%	Results	16
Adverse Events 1:	Adverse Events	0
Total: 23/436 (5.28%)	Adverse Events	1
Neutropenia G 3; Leucopenia G2 1/436 (0.23%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	0-11
Hyperbilirrubinemia  [1]1/436 (0.23%)	Adverse Events	3
Supraventricular arrhythmia NOS  [2]1/436 (0.23%)	Adverse Events	4
supraventricular arrhythmia	HP:0005115	0-27
Heart failure  [2]0/436 (0.00%)	Adverse Events	5
heart	UBERON:0000948	0-5
Infarction and cardiac arrest 0/436 (0.00%)	Adverse Events	6
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	15-29
Ischemia cardiac/Infarction  [3]1/436 (0.23%)	Adverse Events	7
ischemia	DOID:326	0-8
Coronary vasospam  [3]1/436 (0.23%)	Adverse Events	8
Gastroenteritis and renal insuficience 1/436 (0.23%)	Adverse Events	9
gastroenteritis	DOID:2326	0-15
Adverse Events 2:	Adverse Events	10
Total: 6/425 (1.41%)	Adverse Events	11
Neutropenia G 3; Leucopenia G2 0/425 (0.00%)	Adverse Events	12
neutropenia	HP:0001875,DOID:1227	0-11
Hyperbilirrubinemia  [1]0/425 (0.00%)	Adverse Events	13
Supraventricular arrhythmia NOS  [2]0/425 (0.00%)	Adverse Events	14
supraventricular arrhythmia	HP:0005115	0-27
Heart failure  [2]1/425 (0.24%)	Adverse Events	15
heart	UBERON:0000948	0-5
Infarction and cardiac arrest 1/425 (0.24%)	Adverse Events	16
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	15-29
Ischemia cardiac/Infarction  [3]0/425 (0.00%)	Adverse Events	17
ischemia	DOID:326	0-8
Coronary vasospam  [3]0/425 (0.00%)	Adverse Events	18
Gastroenteritis and renal insuficience 0/425 (0.00%)	Adverse Events	19
gastroenteritis	DOID:2326	0-15
